Cortechs.ai | Cortechs.ai announces major NeuroQuant<sup>®</sup> software release

Cortechs.ai announces major NeuroQuant® software release

NeuroQuant 2.0 features new and refreshed set of brain volume reports, provides a broader and continuous age range, offers improved segmentation reproducibility and delivers multiplatform support

(SAN DIEGO) June 2, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce the release of NeuroQuant® 2.0. This major software release marks a significant upgrade to the current version of NeuroQuant. It provides new and improved output reports, debuts the advanced Dynamic Atlas™ segmentation and registration technology, increases the accuracy and precision of brain segmentation and offers operating system independence.

“Advancing the standard for quantitative brain imaging to improve the assessment of neurodegenerative diseases is at the heart of Cortechs.ai,” said Guri Stark, Cortechs.ai’ CEO. “We are excited to expand the current capabilities of NeuroQuant and introduce the Dynamic Atlas, a new and innovative approach to brain segmentation across a broad range of parameters. This release further establishes NeuroQuant as the paramount measurement solution providing quantitative information for the assessment of neurological conditions, from brain development anomalies to Alzheimer’s, multiple sclerosis, epilepsy and brain trauma.”

NeuroQuant 2.0 features and benefits:

Dynamic Atlas – The next generation in standardized and reproducible quantitative brain volume segmentation. The Dynamic Atlas is a new and unique multifactorial processing approach that allows for greater variability in anatomy due to brain development, age or gender. This technology enables the use of age-matched volumetric reports for patients as young as 3 years of age.

New and refreshed brain volume reports – The reports have a fresh new look and 3 new reports have been added, providing a larger set of volume measurements and normative comparisons of subcortical structures, to better aid in the assessment of a broader range of clinical neurological conditions.

Improved subcortical segmentation reproducibility – Increased accuracy, consistency and repeatability of longitudinal studies for long-term patient follow-up, even when the scanner software or manufacturer changes.

Operating system independence – NeuroQuant now operates on Windows, Mac or Linux, providing flexibility in operating platform software thereby reducing the need to acquire new hardware or operate in mixed hardware environment.New licensing approach – The new, flexible licensing structure allows two reports to be run with one upload, saving both money and time, as well as the ability to purchase unlimited access to all reports.

For more information on the NeuroQuant 2.0 release, visit cortechs.ai/neuroquant or contact support@cortechs.ai.

About Cortechs.ai

Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a first FDA 510(k) cleared and CE marked medical device software that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. NeuroQuant automates the process of measuring brain structure volumes from MRI scans. Brain structure volumes increase in childhood development, and later in life, are diminished by neurodegenerative, such as Alzheimer’s, epilepsy, multiple sclerosis and brain trauma.

NeuroQuant brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. It provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to measure volumes and assess the presence of atrophy of brain structures in minutes.

Please visit cortechs.ai for further information.

###

Media Contact:
Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

Scroll to Top